Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1953926 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $31.09Day −3.72%Mkt cap $2.0B1Y +93.7%Off 52W high −30.3%Vol (1Y) 111.4%
Daily closing price, split-adjusted to the current basis; 1.8y shown of 1,673 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest19.3% of sh out |
| Days to cover12.5d |
| 13F net flow (QoQ)+14.58% |
| Top-10 13F concentration65.7% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$10.0M |
| Earnings (TTM)-$425.2M |
| ROE−136.2% |
| Net margin−3777.4% |
| Debt / equity0.32× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−14.4% |
| 1Y+93.7% |
| 3Y+71.3% |
| 5Y+71.3% |
| 10Y+40.0% |
| Since incept. (ann.)+4.0% |
Total return through 2026-07-29 · series begins 2015-06-23. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)111.4% |
| Ann. volatility (3Y)107.2% |
| Sharpe (1Y)1.20 |
| Sharpe (3Y)0.84 |
| Max drawdown (1Y)−64.8% |
| Max drawdown (3Y)−75.0% |
| Beta (3Y vs SPY)−1.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 9.1M | $178M | 14.39% | +17.9% |
| SR One Capital Management, LP | 5.0M | $98M | 7.98% | +0.0% |
| NEA Management Company, LLC | 4.0M | $79M | 6.37% | +14.2% |
| ENAVATE SCIENCES GP, LLC | 3.9M | $77M | 6.21% | +0.0% |
| FEDERATED HERMES, INC. | 3.1M | $61M | 4.95% | +15.2% |
| Polar Capital Holdings Plc | 2.5M | $50M | 4.04% | +141.0% |
| Capital International Investors | 2.4M | $48M | 3.86% | new |
| Fairmount Funds Management LLC | 2.4M | $46M | 3.74% | +6.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$1.46 | — | — | — |
| 2025-12-31 | 2026-03-16 | — | — | $0 | — |
| 2025-09-30 | 2025-11-12 | −$1.22 | — | $0 | — |
| 2025-06-30 | 2025-08-12 | −$1.25 | — | $0 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
